中国血液净化

中国血液净化 ›› 2020, Vol. 19 ›› Issue (11): 775-778.doi: 10.3969/j.issn.1671-4091.2020.11.014

• 指南解读 • 上一篇    下一篇

肾病患者碘对比剂应用共识解读

王旭1,罗冬平1,郭晓凯1,徐家云1   

  1. 1河南科技大学第一附属医院肾脏内科
  • 收稿日期:2020-07-23 修回日期:2020-08-18 出版日期:2020-11-12 发布日期:2020-11-05
  • 通讯作者: 徐家云 wz199054@163.com E-mail:wangxu900601@163.com

Interpretation of the consensus about the use of iodinated contrast media in kidney disease patients

  1. 1Department of Nephrology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China
  • Received:2020-07-23 Revised:2020-08-18 Online:2020-11-12 Published:2020-11-05
  • Contact: xu jiayun E-mail:wangxu900601@163.com

PDF

848

摘要： 【摘要】急性肾损伤是血管内应用对比剂后最常见不良反应之一，尤其在肾病患者中风险增加。如何降低其风险一直是临床关注的重点。2020 年1 月美国放射学会与美国肾脏病基金会联合发布肾病患者碘对比剂应用共识，从定义、诊断标准、危险因素、合并用药、预防措施、特殊人群等方面进行更新阐述。本文结合国内外其他相关指南及文献，对其进行解读。

关键词: 碘对比剂, 急性肾损伤, 慢性肾脏病

Abstract: 【Abstract】Acute kidney injury is one of the most common adverse reaction after intravascular administration of contrast media, especially with increased risk in kidney disease patients. How to reduce the risk has always been an important issue in clinical practice. In January 2020, the American College of Radiology and the National Kidney Foundation issued consensus statements about use of iodinated contrast media in patients with kidney disease. These statements update the definition, diagnostic criteria, risk factors, combined use of drugs, preventive measures, special population and other aspects. This paper interprets these statements in association with other guidelines and relevant literature.

Key words: Iodinated contrast media, Acute kidney injury, Chronic kidney disease

中图分类号: